IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$494.26 USD
+0.46 (0.09%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $495.29 +1.03 (0.21%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth C Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
IDXX 494.26 +0.46(0.09%)
Will IDXX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for IDXX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IDXX
Penumbra's (PEN) New Launch to Enhance Blood Clot Removal
Reasons Why You Should Retain HealthEquity (HQY) Stock for Now
IDXX: What are Zacks experts saying now?
Zacks Private Portfolio Services
GE HealthCare's (GEHC) New Tie-Up to Boost Patient Outcomes
What Lies Ahead of IDEXX Laboratories (IDXX) in Q1 Earnings?
TMO vs. IDXX: Which Stock Is the Better Value Option?
Other News for IDXX
Baron Focused Growth Fund Q1 2024 Shareholder Letter
Eaton Vance Worldwide Health Sciences Fund Bolsters Position in IDEXX Laboratories
Top 10 most oversold S&P 500 stocks
Commit To Buy Idexx Laboratories At $320, Earn 1.4% Annualized Using Options
$1000 Invested In IDEXX Laboratories 10 Years Ago Would Be Worth This Much Today